Fate Therapeutics
Skip to content
About Us
Overview
Leadership
Corporate Responsibility
Pipeline
Overview
Product Candidates
FT819
FT825
FT836
FT839
FT522
Early/Expanded Access Policy
Science
Our Cells of Interest
iPSC Platform
Manufacturing
Publications & Presentations
Patients
Our Commitment
Our Therapy
Autoimmune Disease
Cancer
Clinical Trials
Collaborations
Careers and Culture
The Fate Way
Join Our Team
Investors
About Fate
Press Releases
Events & Presentations
Financials & Filings
SEC Filings
Annual Reports and Proxies
Corporate Governance
Stock Information
Historical Stock Lookup
Investors FAQs
Contact
Sarah Cannon Research Institute (SCRI) – Oncology Partners
About Us
Overview
Leadership
Corporate Responsibility
Pipeline
Overview
Product Candidates
FT819
FT825
FT836
FT839
FT522
Early/Expanded Access Policy
Science
Our Cells of Interest
iPSC Platform
Manufacturing
Publications & Presentations
Patients
Our Commitment
Our Therapy
Autoimmune Disease
Cancer
Clinical Trials
Collaborations
Careers and Culture
The Fate Way
Join Our Team
Investors
About Fate
Press Releases
Events & Presentations
Financials & Filings
SEC Filings
Annual Reports and Proxies
Corporate Governance
Stock Information
Historical Stock Lookup
Investors FAQs
Contact
Sarah Cannon Research Institute (SCRI) – Oncology Partners
MENU
About Us
Overview
Leadership
Corporate Responsibility
Pipeline
Overview
Product Candidates
FT819
FT825
FT836
FT839
FT522
Early/Expanded Access Policy
Science
Our Cells of Interest
iPSC Platform
Manufacturing
Publications & Presentations
Patients
Our Commitment
Our Therapy
Autoimmune Disease
Cancer
Clinical Trials
Collaborations
Careers and Culture
The Fate Way
Join Our Team
Investors
About Fate
Press Releases
Events & Presentations
Financials & Filings
SEC Filings
Annual Reports and Proxies
Corporate Governance
Stock Information
Historical Stock Lookup
Investors FAQs
Contact